DE60038290D1 - Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen - Google Patents
Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungenInfo
- Publication number
- DE60038290D1 DE60038290D1 DE60038290T DE60038290T DE60038290D1 DE 60038290 D1 DE60038290 D1 DE 60038290D1 DE 60038290 T DE60038290 T DE 60038290T DE 60038290 T DE60038290 T DE 60038290T DE 60038290 D1 DE60038290 D1 DE 60038290D1
- Authority
- DE
- Germany
- Prior art keywords
- tramadol
- bimodally
- opioid agonist
- acting opioid
- opioidant
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
- G01N33/9486—Analgesics, e.g. opiates, aspirine
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2500/00—Screening for compounds of potential therapeutic value
- G01N2500/10—Screening for compounds of potential therapeutic value involving cells
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Molecular Biology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Animal Behavior & Ethology (AREA)
- Urology & Nephrology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Emergency Medicine (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Microbiology (AREA)
- Analytical Chemistry (AREA)
- Food Science & Technology (AREA)
- Physics & Mathematics (AREA)
- Pain & Pain Management (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- General Chemical & Material Sciences (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/306,164 US20010006967A1 (en) | 1992-09-21 | 1999-05-06 | Method of simultaneously enhancing analgesic potency and attenuating adverse side effects caused by tramadol and other bimodally-acting opioid agonists |
PCT/US2000/012493 WO2000067739A2 (en) | 1999-05-06 | 2000-05-05 | Opioid antagonists containing compositions for enhancing analgesic potency of tramadol and attenuating its adverse side effects |
Publications (1)
Publication Number | Publication Date |
---|---|
DE60038290D1 true DE60038290D1 (de) | 2008-04-24 |
Family
ID=23184116
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE60038290T Expired - Lifetime DE60038290D1 (de) | 1999-05-06 | 2000-05-05 | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen |
Country Status (8)
Country | Link |
---|---|
US (1) | US20010006967A1 (de) |
EP (1) | EP1178803B1 (de) |
JP (1) | JP2002544160A (de) |
AT (1) | ATE388707T1 (de) |
AU (1) | AU782533B2 (de) |
CA (1) | CA2373348A1 (de) |
DE (1) | DE60038290D1 (de) |
WO (1) | WO2000067739A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
ATE323491T1 (de) * | 1997-12-22 | 2006-05-15 | Euro Celtique Sa | Peroral zu verabreichende arzneiform enthaltend eine kombination von einem opioid agonisten und naltrexon |
AR031682A1 (es) * | 1999-11-19 | 2003-10-01 | Reckitt Benckiser Helthcare Uk | Composiciones farmaceuticas |
ITMI20010907A1 (it) * | 2001-05-02 | 2002-11-02 | Valpharma Sa | Impiego di antagonisti oppioidi per la prevenzione ed il controllo degli effetti collaterali prodotti dagli oppioidi |
CA2778114A1 (en) * | 2001-05-11 | 2002-11-21 | Endo Pharmaceuticals, Inc. | Abuse-resistant opioid dosage form |
ATE493130T1 (de) | 2001-05-11 | 2011-01-15 | Endo Pharmaceuticals Inc | Opioid enthaltende arzneiform gegen missbrauch |
MXPA04000584A (es) | 2001-07-18 | 2004-04-20 | Euro Celtique Sa | COMBINACIONES FARMACeUTICAS DE OXICODONA Y NALOXONA. |
US20030157168A1 (en) | 2001-08-06 | 2003-08-21 | Christopher Breder | Sequestered antagonist formulations |
DE10141650C1 (de) | 2001-08-24 | 2002-11-28 | Lohmann Therapie Syst Lts | Transdermales Therapeutisches System mit Fentanyl bzw. verwandten Substanzen |
US20060177381A1 (en) * | 2002-02-15 | 2006-08-10 | Howard Brooks-Korn | Opiopathies |
ES2627298T3 (es) | 2002-04-05 | 2017-07-27 | Mundipharma Pharmaceuticals S.L. | Preparación farmacéutica que contiene oxicodona y naloxona |
US20040202717A1 (en) | 2003-04-08 | 2004-10-14 | Mehta Atul M. | Abuse-resistant oral dosage forms and method of use thereof |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
CA2544733A1 (en) * | 2003-10-09 | 2005-04-21 | Inverseon, Inc. | Methods for treating diseases and conditions with inverse agonists and for screening for agents acting as inverse agonists |
US20070276024A1 (en) * | 2003-10-09 | 2007-11-29 | Inverseon , Inc. | Methods for Treating Diseases and Conditions with Inverse Agonists and for Screening for Agents Acting as Inverse Agonists |
EP1604666A1 (de) | 2004-06-08 | 2005-12-14 | Euro-Celtique S.A. | Opioide zur Behandlung der chronischen obstruktiven Lungenkrankheit |
JP5132310B2 (ja) | 2004-09-08 | 2013-01-30 | スパイナル・モデュレーション・インコーポレイテッド | 神経刺激の方法及びシステム |
US9205261B2 (en) | 2004-09-08 | 2015-12-08 | The Board Of Trustees Of The Leland Stanford Junior University | Neurostimulation methods and systems |
US20120277839A1 (en) | 2004-09-08 | 2012-11-01 | Kramer Jeffery M | Selective stimulation to modulate the sympathetic nervous system |
US7528175B2 (en) * | 2004-10-08 | 2009-05-05 | Inverseon, Inc. | Method of treating airway diseases with beta-adrenergic inverse agonists |
EP1702558A1 (de) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Verfahren und Vorrichtung zur Darmtätigkeitserfassung |
EP2007389A2 (de) * | 2006-04-14 | 2008-12-31 | Shire LLC | Zusammensetzungen und verfahren zur verstärkung der analgetischen wirkung kovalent gebundener verbindungen, verminderung ihrer nebenwirkungen und verhinderung ihres missbrauchs |
EP1897543A1 (de) | 2006-08-30 | 2008-03-12 | Euro-Celtique S.A. | Buprenorphine-Waffel zur Substitutionstherapie |
US9314618B2 (en) | 2006-12-06 | 2016-04-19 | Spinal Modulation, Inc. | Implantable flexible circuit leads and methods of use |
AU2007329253B2 (en) | 2006-12-06 | 2014-03-27 | Spinal Modulation, Inc. | Delivery devices, systems and methods for stimulating nerve tissue on multiple spinal levels |
US9427570B2 (en) | 2006-12-06 | 2016-08-30 | St. Jude Medical Luxembourg Holdings SMI S.A.R.L. (“SJM LUX SMI”) | Expandable stimulation leads and methods of use |
CN101678203A (zh) | 2007-01-29 | 2010-03-24 | 脊髓调制公司 | 无缝合线引线保持构造 |
KR20140054312A (ko) * | 2007-02-12 | 2014-05-08 | 디엠아이 바이오사이언시스 인코포레이티드 | 조루 및 발기부전을 동시에 치료하는 방법 |
MX2009008511A (es) | 2007-02-12 | 2010-01-20 | Dmi Biosciences Inc | Reduccion de efectos secundarios de tramadol. |
WO2009106831A2 (en) | 2008-02-28 | 2009-09-03 | Syntropharma Limited | Pharmaceutical composition |
AU2009320106B2 (en) | 2008-10-27 | 2016-01-07 | Spinal Modulation, Inc. | Selective stimulation systems and signal parameters for medical conditions |
KR20110133602A (ko) | 2009-03-10 | 2011-12-13 | 유로-셀티큐 에스.에이. | 옥시코돈 및 날록손을 포함하는 즉시 방출 제약 조성물 |
WO2010111358A2 (en) | 2009-03-24 | 2010-09-30 | Spinal Modulation, Inc. | Pain management with stimulation subthreshold to parasthesia |
JP5711221B2 (ja) | 2009-05-15 | 2015-04-30 | スパイナル・モデュレーション・インコーポレイテッドSpinal Modulation Inc. | 脊髄組織を神経調節する方法、システム、およびデバイス |
WO2011087755A2 (en) | 2009-12-22 | 2011-07-21 | Pondera Biotechnologies, LLC | Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications |
JP6231384B2 (ja) | 2010-05-10 | 2017-11-15 | スパイナル・モデュレーション・インコーポレイテッドSpinal Modulation Inc. | 位置ずれを抑制するための方法、システムおよびデバイス |
WO2012106548A2 (en) | 2011-02-02 | 2012-08-09 | Spinal Modulation, Inc. | Devices, systems and methods for the targeted treatment of movement disorders |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US20140179727A1 (en) | 2012-12-14 | 2014-06-26 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
JP2016525138A (ja) | 2013-07-23 | 2016-08-22 | ユーロ−セルティーク エス.エイ. | 疼痛および腸内ディスバイオシスをもたらす疾患および/または腸内細菌移行に対するリスクを高める疾患に罹患している患者における痛みの治療への使用のためのオキシコドンおよびナロキソンの組み合わせ |
US20200022974A1 (en) | 2018-07-23 | 2020-01-23 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2728240B2 (ja) * | 1988-07-26 | 1998-03-18 | ヘキスト薬品工業株式会社 | ヒトプロテインc変異体及びその製造方法 |
-
1999
- 1999-05-06 US US09/306,164 patent/US20010006967A1/en not_active Abandoned
-
2000
- 2000-05-05 DE DE60038290T patent/DE60038290D1/de not_active Expired - Lifetime
- 2000-05-05 AT AT00932162T patent/ATE388707T1/de not_active IP Right Cessation
- 2000-05-05 WO PCT/US2000/012493 patent/WO2000067739A2/en active IP Right Grant
- 2000-05-05 EP EP00932162A patent/EP1178803B1/de not_active Expired - Lifetime
- 2000-05-05 JP JP2000616766A patent/JP2002544160A/ja not_active Withdrawn
- 2000-05-05 CA CA002373348A patent/CA2373348A1/en not_active Abandoned
- 2000-05-05 AU AU49928/00A patent/AU782533B2/en not_active Ceased
Also Published As
Publication number | Publication date |
---|---|
JP2002544160A (ja) | 2002-12-24 |
WO2000067739A2 (en) | 2000-11-16 |
CA2373348A1 (en) | 2000-11-16 |
US20010006967A1 (en) | 2001-07-05 |
AU4992800A (en) | 2000-11-21 |
AU782533B2 (en) | 2005-08-04 |
EP1178803A2 (de) | 2002-02-13 |
EP1178803B1 (de) | 2008-03-12 |
WO2000067739A3 (en) | 2001-01-25 |
ATE388707T1 (de) | 2008-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE60038290D1 (de) | Opioidantagonisthaltige zusammensetzung zur erhöhung der analgetischen wirksamkeit von tramadol und verringerung von ihre nebenwirkungen | |
DE60234183D1 (de) | Verwendung von methylnaltrexon zur behandlung von immunsuppression | |
WO2001037785A3 (en) | Novel methods and compositions involving opioids and antagonists thereof | |
YU42402A (sh) | Jedinjenja karbamida koja imaju antagonističku aktivnost na muskarinski receptor | |
SI1691892T1 (sl) | Varnostna koekstrudirana dozirna oblika, ki vsebuje aktivno sredstvo in protisredstvo, in postopek njene izdelave | |
MX2009004965A (es) | Formas de dosificacion y co-administracion de un agonista de opioides y un antagonista de opioides. | |
DK1135153T3 (da) | Anvendelser af EPH-receptorantagonister og -agonister til behandling af vaskulære forstyrrelser | |
MXPA05003501A (es) | Metodos para tratamiento del dolor administrando un antagonista del factor de crecimiento del nervio y un analgesico opioide y composiciones que los contienen. | |
MXPA05010819A (es) | Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable. | |
WO2003037271A3 (en) | Compounds, pharmaceutical compositions and methods of use therefor | |
PL1735278T3 (pl) | Związki receptora histaminowego H3, wytwarzanie i zastosowania terapeutyczne | |
UA86621C2 (ru) | Антагонисты рецептора глюкагона, их получение и терапевтическое применение | |
MXPA04000586A (es) | Combinacion de un atagonista del receptor de aldosterona con un inhibidor de la hmg coa reductasa. | |
NO20035025L (no) | Anvendelse av osteopontin for behandling og/eller for a hindre nevrologiske sykdommer, samt farmasoytisk sammensetning omfattende osteopontin eller en antagonist med osteopontinaktivitet. | |
WO2007056142A3 (en) | Methods of preventing the serotonin syndrome and compositions for use therefor | |
EA200400734A1 (ru) | Способ и композиция для потенциирования действия опиатного анальгетика | |
WO2001001972A3 (en) | SELECTIVE iGluR5 RECEPTOR ANTAGONISTS FOR THE TREATMENT OF MIGRAINE | |
WO2001085150A3 (en) | Opioid antagonist containing composition for enchaching the potency or reducing adverse side effects ofopioid agonists | |
EA200700403A1 (ru) | ТРИЦИКЛИЧЕСКИЕ δ-ОПИОИДНЫЕ МОДУЛЯТОРЫ | |
MXPA03009595A (es) | Uso de antagonistas del canal de sodio neuronal para control de ectoparasitos de animales homeotermicos. | |
EP1262196A3 (de) | Kombination eines Inhibitoren der Monoaminwiederaufnahme und eines Opioidanatagonisten zur Verwendung in Alkoholismus und Alkoholsucht | |
IL145645A0 (en) | N-(2-phenyl-4-amino-butyl)-1-naphthamides as neurokinin-1 receptor antagonists | |
WO2000053148A3 (en) | Methods and compositions for treating erectile dysfunction | |
DE60236077D1 (de) | Analgetische zusammensetzung enthaltend ein opioid und einen natriumkanalblocker | |
WO2006002375A3 (en) | Method of treating ileus by pharmacological activation of cholinergic receptors |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
8332 | No legal effect for de |